METAGENOMI, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.38 USD | -0.16% |
|
-2.60% | -.--% |
| May. 14 | Metagenomi, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 07 | HC Wainwright Starts Metagenomi With Buy Rating, $10 Price Target | MT |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 239 | - | - |
| Enterprise Value (EV) 1 | 239 | 239 | 239 |
| P/E ratio | -1.9 x | -1.96 x | -2.64 x |
| Yield | - | - | - |
| Capitalization / Revenue | 6.08 x | 7.6 x | 5.03 x |
| EV / Revenue | 6.08 x | 7.6 x | 5.03 x |
| EV / EBITDA | -2.06 x | -1.55 x | - |
| EV / FCF | -5.83 x | -2.6 x | -4.11 x |
| FCF Yield | -17.2% | -38.4% | -24.3% |
| Price to Book | - | - | - |
| Nbr of stocks (in thousands) | 37,464 | - | - |
| Reference price 2 | 6.380 | 6.380 | 6.380 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 44.76 | 39.33 | 31.45 | 47.54 |
| EBITDA 1 | - | -74.28 | -115.8 | -154.5 | - |
| EBIT 1 | - | -78.49 | -121.2 | -146 | -154.6 |
| Operating Margin | - | -175.38% | -308.17% | -464.37% | -325.08% |
| Earnings before Tax (EBT) 1 | - | -60.23 | -110.3 | -141.5 | -154.6 |
| Net income 1 | -43.59 | -68.26 | -111.9 | -143.5 | -158.6 |
| Net margin | - | -152.5% | -284.43% | -456.32% | -333.53% |
| EPS 2 | -12.82 | -35.03 | -3.359 | -3.248 | -2.413 |
| Free Cash Flow 1 | - | -101.2 | -41 | -91.8 | -58.1 |
| FCF margin | - | -226.17% | -104.25% | -291.91% | -122.2% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 8/3/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 12.4 | 11.16 | 10.98 | 7.375 | 7.375 | 11 | 11 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -20.2 | -29.03 | -27.87 | -32.46 | -32.9 | -30.45 | -30.9 |
| Operating Margin | -162.88% | -260.17% | -253.97% | -440.17% | -446.13% | -276.82% | -280.91% |
| Earnings before Tax (EBT) 1 | -16.57 | -25.15 | -26.18 | -30.85 | -31.4 | -27.86 | -28.54 |
| Net income 1 | -19.29 | -25.15 | -26.18 | -30.85 | -31.4 | -27.86 | -28.54 |
| Net margin | -155.61% | -225.36% | -238.54% | -418.31% | -425.73% | -253.29% | -259.5% |
| EPS 2 | -9.905 | -2.079 | -0.5828 | -0.8113 | -0.8313 | -0.7900 | -0.8200 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/27/24 | 5/14/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -101 | -41 | -91.8 | -58.1 |
| ROE (net income / shareholders' equity) | - | - | -44.6% | -107% | - |
| ROA (Net income/ Total Assets) | - | -17.5% | -26.2% | -51.4% | - |
| Assets 1 | - | 389.6 | 427 | 279.4 | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 9.81 | 15 | 14 | 14 |
| Capex / Sales | - | 21.93% | 38.14% | 44.54% | 29.45% |
| Announcement Date | 8/3/23 | 3/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.38
USD
Average target price
16.83
USD
Spread / Average Target
+163.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 239M | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- MGX Stock
- Financials Metagenomi, Inc.
